Better Health for All

Alnylam's core business delivers exceptional health benefits, with over 0.5 million patients globally on their RNAi therapeutics, and one therapy showing a 28% lower risk of cardiovascular events or death.

The company has zero FDA enforcement actions related to manufacturing or clinical trial management in 2024, and a global injury rate of 0.31 per 100 FTE, significantly lower than the industry average of 1.20. Alnylam ensures high accessibility, with over 97% of U.S. residents having confirmed access to therapies and most patients paying $0 out of pocket. The company aims to reach 90-95% of vulnerable populations through programs like Alnylam Challengers and by designing clinical trials to reflect racial and ethnic diversity. Alnylam demonstrates strong risk transparency by providing user-friendly clinical trial information, plain language summaries, and sharing de-identified patient data with researchers. The company also has exceptional data practices, with a Data Governance Committee overseeing data privacy and a focus on responsible AI use. Alnylam offers comprehensive mental health support, including free Headspace subscriptions and an Employee Assistance Program. It also invests in health education through patient-friendly materials and programs like the 'Family Health History Road Trip'. However, the company's R&D investment for health improvement is not specified as a percentage of budget. While Alnylam promotes employee well-being, its support for the broader healthcare workforce is limited to partnerships and diagnostic access. The company's preventative health measures are primarily focused on genetic testing and family health history, not broader public health prevention. During health crises, Alnylam contributed to humanitarian relief through non-profit organizations, but the scale of donations relative to crisis-related revenue is not provided.

Fair Pay & Worker Respect

Alnylam Pharmaceuticals reported a CEO pay ratio of 39:1 for fiscal year 2024.

The company's global injury rate was 0.31 per 100 full-time employees in 2024, which is equivalent to a TRIR of 0.31 per 200,000 hours. The gender pay gap in U.S. operations is less than 1%. An employee culture survey indicated that 95% of employees are highly or moderately engaged, and 80% recommend Alnylam as a great place to work. Voluntary turnover rates for 2024 ranged from 3.2% for VPs+ to 6.6% for individual contributors. The company has two records of penalties totaling $201,959 since 2000, related to healthcare offenses, with the most recent in 2024 for HHS civil monetary penalties and in 2023 for a Medicare Coverage Gap Discount Program violation. Alnylam provides comprehensive health and wellness benefits, including medical, dental, vision, mental health services, and family building support, with 100% of employees having access to these benefits.

Fair Trade & Ethical Sourcing

Alnylam performs a quality audit annually for all suppliers.

The company prohibits child and forced labor across its business and supply chain, requiring suppliers and business partners to adhere to minimum age laws and not engage in forced labor, modern slavery, or human trafficking. No incidents of child or forced labor have been reported in the last three years. Alnylam utilizes serialization and Tracelink software to ensure ongoing traceability across its supply chain. The company's Supplier Code of Conduct, rolled out in 2022, requires suppliers to accept and comply with its ethics, compliance, and corporate responsibility requirements annually. In 2024, Alnylam achieved 4.98% small business spend, with over $41.5 million spent with Small Business Enterprises (SBE).

Kind to Animals

Alnylam Pharmaceuticals conducts animal testing, using nonhuman primates, mice, and rats for pre-clinical drug models.

The company states that nonclinical tests, including animal testing, are used to assess product safety and efficacy and must comply with federal regulations, including the FDA’s good laboratory practice requirements and the Animal Welfare Act. There is no evidence of the company employing validated non-animal testing methods. Alnylam collaborated with AlCana Technologies and MIT researchers on drug development, but there is no indication this collaboration focused on animal-free methods or industry-wide standards. The specific number of animals used annually is not disclosed, but the company's reliance on animal testing for drug development suggests a volume within the negative tiers.

No War, No Weapons

The provided articles, which include corporate responsibility reports and details on grant programs, consistently state that there is no mention or data available regarding Alnylam Pharmaceuticals' involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding initiatives, or any other metrics relevant to the 'No War, No Weapons' ethical value.

Therefore, no specific, concrete data points were found to score any of the KPIs.

Respect for Cultures & Communities

Alnylam engages with over 85 patient advocacy organizations globally, which are considered local community groups, demonstrating extensive formal partnerships.

The company provides multiple channels for reporting concerns, including a 24/7/365 global helpline available online and by phone, allowing for anonymous reporting, indicating comprehensive grievance mechanisms. Alnylam spent 4.98% of its total supplier investment with Small Business Enterprises (SBE), which is less than 5% of procurement spending directed to local suppliers. The company provided $75,000 in donations to nonprofit partner host organizations and $45,000 in corporate charitable donations and matching funds, totaling $120,000, which represents approximately 0.0075% of its $1.6 billion combined net product revenue, falling below the 1-3% threshold for community fund allocation. Alnylam's educational websites, such as The Bridge U.S. and EU, Pinpoint AHP (U.S.), and Living with Porphyria (EU), are available in multiple languages, indicating basic language inclusivity. Employees participate in trainings to build competencies related to cultural awareness and bias recognition, but no completion percentage is provided.

Safe & Smart Tech

Alnylam has no recent security news or data breaches reported by external monitoring.

The company has established a cross-functional internal governance committee to oversee AI adoption and use, with a policy defining scope, principles, roles, and responsibilities, including diversity and non-discrimination. Alnylam conducts annual cybersecurity awareness training for employees. Its cybersecurity program prioritizes vulnerability management. The company mentions a "Privacy By Design" process and a Data Governance Committee focused on data retention and disposal. Alnylam states its commitment to compliance with relevant laws and regulations, including those related to data privacy and confidentiality, and discusses extensive regulatory compliance requirements in the US and EU. The company aims for transparency in AI use, including disclaimers when AI-generated content is used.

Zero Waste & Sustainable Products

Alnylam's non-hazardous waste diversion rate was 22% in 2024.

The company accepted approximately 0.5% of all shipped vials as returned product in 2021. Alnylam has implemented several waste reduction initiatives, including recycling 440 gallons of waste ethanol, eliminating insulated shippers to reduce 48,500 pounds of plastic and carton waste, partnering with Furniture Trust and Seeding Labs to divert equipment, collecting over 2,400 pounds of e-waste, and implementing electronic patient information leaflets saving 31,000 pages of paper in 2024. In 2020, Alnylam safely managed and disposed of 992,000 pounds of hazardous materials via recycling, treatment, and incineration. The company reduced approximately 37,000 kg of plastic and carton waste annually by reducing insulated shippers in European operations. Alnylam has company-wide waste reduction targets to minimize waste and increase reuse and recycling. The company requires all tier-1 suppliers to comply with ethics, safety, quality, anti-corruption, information security, and non-disclosure policies. Basic disposal information is provided on some products.